US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.86

+0.20501.10%

Volume:10K

Turnover:183.80K

Market Cap:109.41M

PE:- -

High:18.86

Open:18.85

Low:18.67

Close:18.66

52wk High:21.88

52wk Low:14.38

Shares:5.80M

Float Shares:5.80M

Volume Ratio:0.36

T/O Rate:0.17%

Dividend:0.71

Dividend Rate:3.79%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

WuXi Biologics Files HKEX Next-Day Disclosure Return, Share Capital Rises by 2,423,900 Shares

Wuxi Biologics (Cayman) Stock Advances 3.0% in Hong Kong

CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong

Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support

Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study

THOMSON REUTERS

Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc

THOMSON REUTERS

Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab

THOMSON REUTERS

WuXi Biologics Files HKEX Next-Day Disclosure Return Reporting 1,527,500 New Shares Issued Via Option Exercises

CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China

Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme

Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties

CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China

MT Newswires Live

CSPC Pharma Initiates Depression Drug Candidate Trial in China

MT Newswires Live

CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for R/M Hnscc

THOMSON REUTERS

BeiGene Expands Access to Innovative Cancer Therapy Through New U.S. Agreement

CSPC Pharma Begins Trial for Weight Management Drug in China

MT Newswires Live

CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff

CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug

CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/KURE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.86,"timestamp":1788463137857,"preClose":18.655,"halted":0,"volume":9790,"delay":0,"changeRate":0.010989010989010896,"floatShares":5800979,"shares":5800979,"eps":0,"marketStatus":"Trading","change":0.205,"latestTime":"09-03 15:23:07 EDT","open":18.85,"high":18.86,"low":18.6655,"amount":183800.00540000002,"amplitude":0.010426,"askPrice":18.92,"askSize":100,"bidPrice":18.7,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":18.655,"sharesOutstanding":4750002,"nav":18.46,"aum":108936686.05,"dividendRate":0.0379,"bidAskSpread":0.00342,"postHourTrading":{"tag":"盘后","latestPrice":18.655,"preClose":18.655,"latestTime":"19:30 EDT","volume":10,"amount":186.55,"timestamp":1788391804434,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.361317,"impliedVol":0.2767,"impliedVolPercentile":0.5754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5800979,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.361317,"shares":5800979,"dividePrice":0.7148,"high":18.86,"amplitude":0.010426,"preClose":18.655,"low":18.6655,"week52Low":14.3797,"pbRate":"--","week52High":21.875,"institutionHeld":0,"latestPrice":18.86,"committee":0.6,"eps":0,"divideRate":0.0379,"volume":9790,"delay":0,"ttmEps":0,"open":18.85,"prevYearClose":17.04,"prevWeekClose":18.925,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":19.215,"twentyDayClose":17.47,"sixtyDayClose":14.5156},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664870477","title":"WuXi Biologics Files HKEX Next-Day Disclosure Return, Share Capital Rises by 2,423,900 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664870477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664870477?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:21","pubTimestamp":1788445293,"startTime":"0","endTime":"0","summary":"WuXi Biologics files HKEX next-day disclosure return, share capital rises by 2,423,900 sharesWuXi Biologics filed a next-day disclosure return dated Sept. 3, 2026, reporting 2,423,900 new ordinary sha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL39VqKV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1688375341.USD","LU0307460666.USD","LU1720050803.USD","LU1242518931.SGD","LU0588546209.SGD","LU0029874061.USD","LU0708995583.HKD","LU0516422366.SGD","LU0326950275.SGD","LU1242518857.USD","LU0823426480.USD","LU0140636845.USD","LU0128526141.USD","LU0348735423.USD","LU0572944931.SGD","LU0043850808.USD","LU3063872942.SGD","LU1794554557.SGD","LU2039709279.SGD","LU0051755006.USD","LU0516423174.USD","LU0456846285.SGD","BK1576","LU0327786744.USD","LU0516423091.SGD","KURE","BK1521","SG9999002463.SGD","LU0979878070.USD","LU0856984785.SGD","LU0516422440.USD","BK1589","LU0039217434.USD","LU0181495838.USD","LU0823426308.USD","LU0348825331.USD","LU0417516902.SGD","LU0819121731.USD","LU0516422952.EUR","BK1610","LU0320764599.SGD","LU0456827905.SGD","LU0359201612.USD","02269","BK1141","LU1880383366.USD","LU0052750758.USD","IE00B0JY6N72.USD","LU0359202008.SGD","SG9999002562.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664827703","title":"Wuxi Biologics (Cayman) Stock Advances 3.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2664827703","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664827703?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:32","pubTimestamp":1788424320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. advanced 3.0% to 50.70 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25213.31.Wuxi Biologics  Inc. closed 6.9% short of its 52-week high of HK$54.45, which the company reached Aug. 26.Trading volume totaled 44.0 million shares, compared to the 50-day average of 38.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU0456846285.SGD","LU0052750758.USD","LU0307460666.USD","LU0039217434.USD","LU0456827905.SGD","LU0348825331.USD","LU0359202008.SGD","LU0823426308.USD","LU0979878070.USD","LU1242518857.USD","LU0516423091.SGD","LU2039709279.SGD","LU0516422440.USD","LU0819121731.USD","SG9999002463.SGD","LU0326950275.SGD","LU0572944931.SGD","LU0708995583.HKD","LU0320764599.SGD","BK1589","LU1794554557.SGD","02269","BK1610","LU0348735423.USD","IE00B0JY6N72.USD","LU0359201612.USD","LU1720050803.USD","SG9999002562.SGD","LU0140636845.USD","LU0823426480.USD","LU0051755006.USD","LU0327786744.USD","LU0417516902.SGD","BK1576","LU0516422366.SGD","LU0516423174.USD","BK1521","LU0516422952.EUR","LU0181495838.USD","LU0043850808.USD","LU0856984785.SGD","LU1688375341.USD","LU1880383366.USD","LU3063872942.SGD","LU0588546209.SGD","KURE","LU1242518931.SGD","LU0128526141.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664827084","title":"CSPC Pharmaceutical Group Stock Climbs 4.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2664827084","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664827084?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:31","pubTimestamp":1788424260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. rallied 4.8% to 9.61 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25213.31.The stock's rise snapped a four-day losing streak.CSPC Pharmaceutical Group Ltd. closed 17% below its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 6.3%, SSY Group Ltd. rose 0.2%, and United Laboratories International Holdings Ltd. rose 0.1%.Trading volume totaled 134.9 million shares, compared to the 50-day average of 105.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU1008478684.HKD","LU1328277881.USD","LU0072913022.USD","LU1993786604.SGD","LU1226288170.HKD","LU1960683339.HKD","LU0326950275.SGD","LU1226287875.USD","LU1807302812.USD","BK1191","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","IE00B031HY20.USD","SG9999004220.SGD","01093","LU1226287529.USD","IE00B5MMRT66.SGD","LU0067412154.USD","LU0880133367.SGD","IE00BZ08YT58.USD","LU1226288253.USD","KURE","IE0008368742.USD","LU1813983027.USD","LU1226287792.SGD","IE00BZ08YS42.EUR","LU0140636845.USD","IE0008369823.USD","LU0315179316.USD","LU0501845795.SGD","LU1152091754.HKD","BK1521","LU0314109678.HKD","HK0000165453.HKD","IE00BZ08YR35.GBP","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128427781","title":"Clinical Data Readouts Take Center Stage as Chinese Biotech Firms Surge; CSPC Pharma Climbs Over 4% While Huabao's HK Biotech ETF Holds Key Support","url":"https://stock-news.laohu8.com/highlight/detail?id=1128427781","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128427781?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:00","pubTimestamp":1788404450,"startTime":"0","endTime":"0","summary":"Hong Kong-listed innovative drug stocks continued their upward momentum on September 3rd, with leading biotech names pushing the sector higher. CSPC Pharma and Sino Biopharmaceutical both advanced...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","LU0314109678.HKD","LU1807302812.USD","01093","IE0008368742.USD","IE0008369823.USD","159316","BK1161","LU1226287875.USD","LU1008478684.HKD","LU1328277881.USD","IE00B5MMRT66.SGD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU0072913022.USD","LU0067412154.USD","06978","LU0315179316.USD","LU1960683339.HKD","IE00B543WZ88.USD","LU1226287529.USD","LNGR","520880","LU1226288253.USD","BK1191","LU1152091754.HKD","LU1152091168.USD","159992","FLHK","LU0501845795.SGD","LU1813983027.USD","LU0880133367.SGD","LU1951186391.HKD","IE00BZ08YS42.EUR","BK1574","IE00B031HY20.USD","LU0326950275.SGD","LU1226288170.HKD","LU2039709279.SGD","IBBQ","BK1515","IE00BZ08YT58.USD","BK1521","LU0140636845.USD","KURE","MEDX","LU1993786604.SGD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664440588","title":"Akeso - Ivonescimab Meets Os Key Secondary Endpoint in Harmoni-2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664440588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664440588?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:02","pubTimestamp":1788390131,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U147:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348766576.USD","IE00BPRC5H50.USD","LU0540923850.HKD","LU2476274720.SGD","LU0634319403.HKD","BK1161","LU0348825331.USD","IE00B543WZ88.USD","LU2488822045.USD","LU0561508036.HKD","LU0348827113.USD","BK1574","LU0417516738.SGD","LU2399975544.HKD","LU1961090484.USD","LU2476274308.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","KURE","LU0348783233.USD","LU2778985437.USD","LU0348784397.USD","LU0348735423.USD","LU1720050803.USD","LU0348767384.USD","LU1794554557.SGD","09926","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841457","title":"Akeso Says Ivonescimab Meets Overall Survival Endpoint in Phase III HARMONi-2 Lung Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841457","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841457?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:01","pubTimestamp":1788382889,"startTime":"0","endTime":"0","summary":"Akeso says ivonescimab meets overall survival endpoint in Phase III HARMONi-2 lung cancer trialAkeso reported its Phase III HARMONi-2 trial met a key overall survival endpoint in an interim analysis v","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL9yKX9v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B543WZ88.USD","LU0634319403.HKD","BK1574","BK1161","LU2476274308.USD","LU1961090484.USD","LU0348783233.USD","LU0417516738.SGD","LU0348735423.USD","LU0417516571.SGD","LU0540923850.HKD","IE00B5MMRT66.SGD","KURE","LU0348766576.USD","LU0348827113.USD","LU0348784397.USD","LU1720050803.USD","LU0417516902.SGD","LU2488822045.USD","LU0348825331.USD","LU0561508036.HKD","IE00BPRC5H50.USD","LU2778985437.USD","LU1794554557.SGD","LU2399975544.HKD","LU2476274720.SGD","LU0348767384.USD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664684112","title":"Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line Pd-L1-Positive Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2664684112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664684112?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382834,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2399975544.HKD","LU0348783233.USD","LU0417516902.SGD","LU0561508036.HKD","LU0417516571.SGD","BK1161","LU2476274720.SGD","09926","IE00B5MMRT66.SGD","BK1574","LU0348766576.USD","LU1794554557.SGD","LU0634319403.HKD","LU2488822045.USD","LU0348767384.USD","LU0417516738.SGD","KURE","LU2778985437.USD","LU0348735423.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU1720050803.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU2476274308.USD","LU0348825331.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664125841","title":"Akeso - Ivonescimab Demonstrates Statistically Significant Improvement over Pembrolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2664125841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664125841?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:00","pubTimestamp":1788382834,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U140:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348825331.USD","LU2476274720.SGD","LU2399975544.HKD","LU2778985437.USD","LU1794554557.SGD","LU0348827113.USD","LU0561508036.HKD","LU0417516738.SGD","LU0348784397.USD","BK1161","09926","LU1961090484.USD","LU0348767384.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU0417516571.SGD","LU0348783233.USD","LU0348766576.USD","LU2476274308.USD","KURE","LU1720050803.USD","LU0540923850.HKD","LU0634319403.HKD","LU0348735423.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664812235","title":"WuXi Biologics Files HKEX Next-Day Disclosure Return Reporting 1,527,500 New Shares Issued Via Option Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2664812235","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664812235?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:47","pubTimestamp":1788356848,"startTime":"0","endTime":"0","summary":"WuXi Biologics files HKEX next-day disclosure return reporting 1,527,500 new shares issued via option exercisesWuXi Biologics filed a next-day disclosure return on Sept. 2, 2026, reporting 1,527,500 n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL7RgmR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0359201612.USD","BK1589","LU0417516902.SGD","LU0823426308.USD","BK1141","LU0320764599.SGD","LU0708995583.HKD","LU0516422366.SGD","SG9999002463.SGD","LU1242518931.SGD","BK1576","LU3063872942.SGD","LU0052750758.USD","LU0456827905.SGD","LU0307460666.USD","LU0572944931.SGD","BK1521","LU0823426480.USD","LU0856984785.SGD","LU0326950275.SGD","LU0516423091.SGD","LU1794554557.SGD","LU0039217434.USD","02269","LU0456846285.SGD","LU0029874061.USD","LU0417516738.SGD","LU0516422440.USD","KURE","LU0128526141.USD","LU2039709279.SGD","LU0348735423.USD","LU0588546209.SGD","LU0516422952.EUR","LU0051755006.USD","LU0979878070.USD","LU0819121731.USD","LU0140636845.USD","LU1242518857.USD","LU1688375341.USD","LU1720050803.USD","BK1610","LU1880383366.USD","LU0359202008.SGD","LU0327786744.USD","LU0348825331.USD","LU0516423174.USD","SG9999002562.SGD","LU0181495838.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664850737","title":"CSPC Pharmaceutical Initiates Phase I Clinical Trial of Syh2056 Tablets in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664850737","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664850737?lang=en_us&edition=fundamental","pubTime":"2026-09-01 23:56","pubTimestamp":1788278176,"startTime":"0","endTime":"0","summary":"BRIEF-CSPC Pharmaceutical Initiates Phase I Clinical Trial Of SYH2056 Tablets In ChinaSept 1 (Reuters)-CSPC PHARMACEUTICAL GROUP LIMITED1093.HK:INITIATES PHASE I CLINICAL TRIAL OF SYH2056 TABLETS FOR DEPRESSION IN CHINAFurther company coverage:1093.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0GT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU1951186391.HKD","LU1226287792.SGD","01093","HK0000165453.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU2039709279.SGD","BK1521","LU0072913022.USD","IE0008369823.USD","LU0501845795.SGD","LU0314109678.HKD","LU1807302812.USD","LU0880133367.SGD","BK1515","LU1960683339.HKD","LU1813983027.USD","LU1226287875.USD","LU1152091754.HKD","LU0315179316.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1226288253.USD","LU1152091168.USD","LU0326950275.SGD","LU1226287529.USD","LU0140636845.USD","LU0067412154.USD","IE0008368742.USD","SG9999004220.SGD","LU1226288170.HKD","KURE","BK1191","LU1008478684.HKD","LU1328277881.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857975","title":"Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857975","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664857975?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:49","pubTimestamp":1788274144,"startTime":"0","endTime":"0","summary":"Innovent Biologics grants 583,731 restricted shares under 2024 share schemeInnovent Biologics granted 59,757 share options, exercisable at HK$ 105.76 per share, with a 10-year exercise period.It also ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL8nZgF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU2097828557.USD","LU0463099449.HKD","HK0000165453.HKD","LU2488822045.USD","LU0326950275.SGD","LU2097828474.EUR","01911","LU2097828631.EUR","LU0244354667.USD","LU2328871848.SGD","01801","LU1969619763.USD","LU2097828805.USD","LU0502904849.HKD","LU2097828714.EUR","BK1161","KURE","LU2242644610.SGD","LU0455707207.USD","LU1188198961.HKD","BK1589","BK1147"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859365","title":"Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859365","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859365?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:17","pubTimestamp":1788265039,"startTime":"0","endTime":"0","summary":"Innovent Biologics files list of board, board committee members with disclosure dutiesInnovent updated its board and committee roster as of Sept. 1, 2026, naming Yu Dechao as chairman, chief executive","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL3jJnGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU2097828714.EUR","BK1583","LU2328871848.SGD","LU0455707207.USD","HK0000165453.HKD","01911","LU2097828474.EUR","LU2097828557.USD","LU2242644610.SGD","LU0463099449.HKD","BK1161","BK1589","LU2097828805.USD","KURE","LU0326950275.SGD","LU1188198961.HKD","LU0244354667.USD","LU2488822045.USD","LU0502904849.HKD","LU1969619763.USD","BK1147","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803853","title":"CSPC Pharma's SYS6010 Gets Breakthrough Therapy Designation for New Indication in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803853","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803853?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:40","pubTimestamp":1788259205,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group's  SYS6010 was granted another Breakthrough Therapy Designation by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The designation is for the drug's proposed indication of recurrent or metastatic head and neck squamous cell carcinoma in patients who have failed prior immunotherapy and platinum-based chemotherapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0008369823.USD","IE0008368742.USD","BK1521","LU0880133367.SGD","LU1008478684.HKD","LU1226287875.USD","LU1807302812.USD","LU1951186391.HKD","LU1960683339.HKD","LU1226288170.HKD","LU0314109678.HKD","BK1191","LU0067412154.USD","LU1226287792.SGD","LU0140636845.USD","LU1226288253.USD","LU0315179316.USD","LU1328277881.USD","LU1226287529.USD","01093","LU1152091168.USD","LU1993786604.SGD","LU1152091754.HKD","HK0000165453.HKD","LU2039709279.SGD","LU0501845795.SGD","LU0326950275.SGD","BK1515","IE00B543WZ88.USD","LU1813983027.USD","SG9999004220.SGD","KURE","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","IE00B031HY20.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664580888","title":"CSPC Pharma Initiates Depression Drug Candidate Trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664580888","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664580888?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:35","pubTimestamp":1788258919,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  officially began a phase 1 clinical trial of SYH2056 tablets for the treatment of depression.The trial in China will study the safety, tolerability, and pharmacokinetic profile of the product, as well as the food effect in healthy participants, according to a Tuesday filing with the Hong Kong bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","LU2039709279.SGD","IE00BZ08YT58.USD","LU1328277881.USD","LU1226287529.USD","IE0008369823.USD","LU0326950275.SGD","SG9999004220.SGD","LU0501845795.SGD","LU0067412154.USD","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1226288253.USD","LU0072913022.USD","LU0140636845.USD","LU1226287792.SGD","KURE","BK1521","LU1152091168.USD","LU0315179316.USD","HK0000165453.HKD","LU1152091754.HKD","IE00B031HY20.USD","IE00B543WZ88.USD","BK1515","IE0008368742.USD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1993786604.SGD","LU1960683339.HKD","LU1813983027.USD","LU1951186391.HKD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1226287875.USD","LU0314109678.HKD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664830037","title":"CSPC Pharmaceutical - Sys6010 Granted Breakthrough Therapy Designation by Nmpa in China for R/M Hnscc","url":"https://stock-news.laohu8.com/highlight/detail?id=2664830037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664830037?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:07","pubTimestamp":1788257224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226288253.USD","LU1813983027.USD","LU0314109678.HKD","LU0315179316.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1328277881.USD","BK1521","LU1951186391.HKD","LU1226287792.SGD","IE0008369823.USD","LU0326950275.SGD","LU1226288170.HKD","LU0501845795.SGD","IE00B543WZ88.USD","LU1807302812.USD","LU1960683339.HKD","LU0880133367.SGD","LU0067412154.USD","LU1152091168.USD","LU1226287529.USD","BK1515","01093","LU1226287875.USD","IE00BZ08YS42.EUR","BK1191","SG9999004220.SGD","KURE","IE00BZ08YT58.USD","LU0140636845.USD","LU2039709279.SGD","HK0000165453.HKD","LU1008478684.HKD","LU1993786604.SGD","LU0072913022.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106179811","title":"BeiGene Expands Access to Innovative Cancer Therapy Through New U.S. Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1106179811","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106179811?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:30","pubTimestamp":1788219019,"startTime":"0","endTime":"0","summary":"BeiGene (06160) has announced a voluntary agreement with the U.S. government, designed to broaden patient access to its innovative cancer treatments under the Medicaid program.The deal is part of a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","LU1251922891.USD","LU1770034418.SGD","LU0828237510.HKD","BK4585","LU0228659784.USD","BK4139","BK4526","LU1969619763.USD","LU0307460666.USD","BK1588","KURE","06160","BK1161","LU1719994722.HKD","LU0588546209.SGD","ONC","LU2328871848.SGD","688235","BK1500","BK0239","BK1583","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003385","title":"CSPC Pharma Begins Trial for Weight Management Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003385","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003385?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:22","pubTimestamp":1788178969,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) officially began a phase I clinical trial of the SYH2092 injection at the first center in China.The drug has been developed for weight management in adult patients with obesity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ08YT58.USD","LU1226288170.HKD","LU1813983027.USD","LU1951186391.HKD","HK0000165453.HKD","LU0140636845.USD","LU1993786604.SGD","LU1328277881.USD","LU0326950275.SGD","LU0314109678.HKD","BK1191","SG9999004220.SGD","LU1226287529.USD","LU1226287792.SGD","LU1807302812.USD","LU1152091168.USD","LU0315179316.USD","LU2039709279.SGD","IE00B543WZ88.USD","LU1152091754.HKD","LU0072913022.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1960683339.HKD","KURE","BK1521","LU1226287875.USD","IE0008369823.USD","LU1008478684.HKD","BK1515","01093","LU1226288253.USD","IE0008368742.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178504231","title":"CSPC Pharma Advances Weight Management Pipeline With Phase 1 Trial Kickoff","url":"https://stock-news.laohu8.com/highlight/detail?id=1178504231","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178504231?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:00","pubTimestamp":1788177626,"startTime":"0","endTime":"0","summary":"CSPC Pharma (01093) has announced the official initiation of the first clinical trial site in China for its Phase 1 study of the SYH2092 injection, targeting weight management in adults who are...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","KURE","LU1226287529.USD","LU0326950275.SGD","LU0880133367.SGD","LU0315179316.USD","BMED","LU0501845795.SGD","LU1226287875.USD","MDTX","IE0008368742.USD","IBBQ","LU2039709279.SGD","LU1226288170.HKD","LU1807302812.USD","PSYK","LU0314109678.HKD","LU1008478684.HKD","BK1191","IBBJ","BK1515","01093","IE00B543WZ88.USD","IE00BZ08YT58.USD","BK1521","LU1328277881.USD","SG9999004220.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU0067412154.USD","LU1152091754.HKD","LU0072913022.USD","LU1226288253.USD","LU1226287792.SGD","LU1152091168.USD","LU1960683339.HKD","LU1993786604.SGD","IE00B031HY20.USD","LU1951186391.HKD","LU0140636845.USD","IE0008369823.USD","LU1813983027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008868","title":"CSPC Pharma Wins China NMPA Clearance to Start Phase 1 Trial of Syh2092 Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008868","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008868?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:53","pubTimestamp":1788177190,"startTime":"0","endTime":"0","summary":"CSPC Pharma wins China NMPA clearance to start Phase 1 trial of SYH2092 obesity drugCSPC received China NMPA clearance in August 2026 to start clinical trials of SYH2092 for weight management in overw","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLnjzPQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","LU0315179316.USD","LU0501845795.SGD","LU2039709279.SGD","LU1008478684.HKD","LU0140636845.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1226287875.USD","SG9999004220.SGD","LU1152091168.USD","BK1515","LU1813983027.USD","IE00BZ08YT58.USD","LU1226287529.USD","IE00B031HY20.USD","HK0000165453.HKD","LU0326950275.SGD","IE0008369823.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU0067412154.USD","01093","BK1191","LU1960683339.HKD","KURE","LU0880133367.SGD","LU0314109678.HKD","IE00B543WZ88.USD","LU1807302812.USD","BK1521","LU1226288253.USD","LU1328277881.USD","LU0072913022.USD","LU1226288170.HKD","LU1152091754.HKD","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663882008","title":"CSPC Pharmaceutical - Initiates Phase I Clinical Trial of Syh2092 Injection for Weight Management in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2663882008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663882008?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:52","pubTimestamp":1788177157,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S098:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BZ08YT58.USD","LU1226288170.HKD","LU1813983027.USD","LU1951186391.HKD","HK0000165453.HKD","LU0140636845.USD","LU1993786604.SGD","LU1328277881.USD","LU0326950275.SGD","LU0314109678.HKD","BK1191","SG9999004220.SGD","LU1226287529.USD","LU1226287792.SGD","LU1807302812.USD","LU1152091168.USD","LU0315179316.USD","LU2039709279.SGD","IE00B543WZ88.USD","LU1152091754.HKD","LU0072913022.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1960683339.HKD","KURE","BK1521","LU1226287875.USD","IE0008369823.USD","LU1008478684.HKD","BK1515","01093","LU1226288253.USD","IE0008368742.USD","LU0880133367.SGD","IE00B5MMRT66.SGD","LU0501845795.SGD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}